Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity

Author(s):  
Ying-Xin Shi ◽  
Xiang-Yu Chen ◽  
Hui-Na Qiu ◽  
Wei-Ran Jiang ◽  
Min-Ying Zhang ◽  
...  
2020 ◽  
Vol 8 ◽  
Author(s):  
Lucia Pacifico ◽  
Francesco Massimo Perla ◽  
Gianmarco Andreoli ◽  
Rosangela Grieco ◽  
Pasquale Pierimarchi ◽  
...  

2021 ◽  
Vol 2 (2) ◽  
pp. 35-39
Author(s):  
David Silas ◽  
Jeremy Park ◽  
Joon Young Kim

Previous studies in adults have found a correlation between nonalcoholic fatty liver disease (NAFLD) and sarcopenia. The present study evaluated the relationship between NFALD and skeletal muscle mass in overweight/obese youth. A total of 234 children and adolescents (age 8-16) was stratified into tertiles based on relative muscle mass (RMM). Total, regional lean body mass, and total fat mass were obtained by dual-energy X-ray absorptiometry. RMM was defined as the percent of muscle mass (kg) relative to the sum of muscle and fat mass (kg). NAFLD was diagnosed via ultrasononography and a subset of participants with NAFLD (n=40) underwent a liver biopsy. The lowest tertile had a significantly higher risk for obesity, dyslipidemia, insulin resistance, metabolic syndrome, NAFLD, and nonalcoholic steatohepatitis (NASH). The present study demonstrated an association between low muscle mass, NAFLD, and NASH in overweight/obese youth. Despite the strong scientific merits of the present study, a lack of race/ethnic description could be a major critique as different ethnic background (specifically in the minorities) may be disproportionately impacted by fat distribution and relative muscle mass. Even though there is a clear relationship between sarcopenia and NAFLD in the elderly, this association may not stem from the same origin in the pediatric population. Lastly, but not least, future studies should evaluate NAFLD in obese youth with varying degrees of metabolic disorders (i.e., metabolic syndrome).


2021 ◽  
Vol 67 (9) ◽  
pp. 1233-1239
Author(s):  
Iasmin dos Santos Barreto ◽  
Raquel Oliveira dos Santos ◽  
Raquel Rocha ◽  
Claudineia de Souza ◽  
Naiade Almeida ◽  
...  

2021 ◽  
Author(s):  
Teruki Miyake ◽  
Masumi Miyazaki ◽  
Osamu Yoshida ◽  
Sayaka Kanzaki ◽  
Hironobu Nakaguchi ◽  
...  

Abstract Background: Causes of non-alcoholic fatty liver disease and its progression include visceral fat accumulation and loss of muscle mass; however, which is more critical is unclear. To clarify this, we examined the relationship between body composition and non-alcoholic fatty liver disease progression as indicated by fibrosis and the non-alcoholic fatty liver disease activity score.Methods: This cross-sectional study comprised 139 patients (54 men; age, 20–76 years) treated for non-alcoholic fatty liver disease between December 2010 and January 2020. Body composition measurements, histological examinations of liver samples, and comprehensive blood chemistry tests were performed. The relationship between body composition and non-alcoholic fatty liver disease histology findings was analyzed using the logistic regression model.Results: Fibrosis was significantly and inversely correlated with muscle mass and appendicular skeletal muscle mass and significantly and positively correlated with fat mass, fat mass/height squared, visceral fat area, and waist-hip ratio (P <0.05). After adjustment for sex, blood chemistry measurements, and body composition indices, fibrosis remained associated with appendicular skeletal muscle mass, fat mass, fat mass/height squared, and visceral fat area (P <0.05). Non-alcoholic fatty liver disease activity score ≥5 significantly correlated with fat mass and fat mass/height squared in a univariate but not multivariate analysis.Conclusions: Fibrosis in non-alcoholic fatty liver disease, an indicator of unfavorable long-term outcomes, is associated with more indices of fat mass than of those of muscle mass. Hence, fat mass should be controlled to prevent non-alcoholic fatty liver disease progression.


Author(s):  
Lindsay T Fourman ◽  
Takara L Stanley ◽  
Isabel Zheng ◽  
Chelsea S Pan ◽  
Meghan N Feldpausch ◽  
...  

Abstract Background Nonalcoholic fatty liver disease (NAFLD) affects more than one-third of people living with human immunodeficiency virus (HIV). Nonetheless, its natural history is poorly understood, including which patients are most likely to have a progressive disease course. Methods We leveraged a randomized trial of the growth hormone–releasing hormone analogue tesamorelin to treat NAFLD in HIV. Sixty-one participants with HIV-associated NAFLD were randomized to tesamorelin or placebo for 12 months with serial biopsies. Results In all participants with baseline biopsies (n = 58), 43% had hepatic fibrosis. Individuals with fibrosis had higher NAFLD Activity Score (NAS) (mean ± standard deviation [SD], 3.6 ± 2.0 vs 2.0 ± 0.8; P &lt; .0001) and visceral fat content (mean ± SD, 284 ± 91 cm2 vs 212 ± 95 cm2; P = .005), but no difference in hepatic fat or body mass index. Among placebo-treated participants with paired biopsies (n = 24), 38% had hepatic fibrosis progression over 12 months. For each 25 cm2 higher visceral fat at baseline, odds of fibrosis progression increased by 37% (odds ratio, 1.37 [95% confidence interval, 1.03–2.07]). There was no difference in baseline NAS between fibrosis progressors and nonprogressors, though NAS rose over time in the progressor group (mean ± SD, 1.1 ± 0.8 vs −0.5 ± 0.6; P &lt; .0001). Conclusions In this longitudinal study of HIV-associated NAFLD, high rates of hepatic fibrosis and progression were observed. Visceral adiposity was identified as a novel predictor of worsening fibrosis. In contrast, baseline histologic characteristics did not relate to fibrosis progression.


2019 ◽  
Vol 3 (8) ◽  
pp. 1061-1072 ◽  
Author(s):  
Julianna C. Hsing ◽  
Mindie H. Nguyen ◽  
Baiyu Yang ◽  
Yan Min ◽  
Summer S. Han ◽  
...  

2019 ◽  
Vol 34 (7) ◽  
pp. 1254-1263 ◽  
Author(s):  
Louise Johanna Maria Alferink ◽  
Katerina Trajanoska ◽  
Nicole Stephanie Erler ◽  
Josje Dorothea Schoufour ◽  
Robert Jacobus Knegt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document